COYA-301 is under clinical development by Coya Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how COYA-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COYA-301 overview
COYA-301 is under development for the treatment of frontotemporal dementia (FTD). It is administered through subcutaneous route. The therapeutic candidate acts by targeting IL-2 receptor.
It was also under development for Alzheimer's disease.
Coya Therapeutics overview
Coya Therapeutics (Coya) is a cellular therapy platform that discovers and develops therapeutics for the treatment of neurodegenerative and autoimmune diseases. Coya is headquartered in Houston, Texas, the US.
For a complete picture of COYA-301’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
